Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Evaluation of Rifampicin and Isoniazid Resistance in Pulmonary Tuberculosis Using Cartridge-Based Nucleic Acid Amplification Test and Line Probe Assay.

Cureus·2026
Same author

Palladium anchored to magnetic silica functionalized with AP groups as a novel and efficient heterogeneous catalyst for C-C coupling reactions.

Scientific reports·2026
Same author

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Future oncology (London, England)·2026
Same author

Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer.

Clinical genitourinary cancer·2026
Same author

A Cross-sectional Study to Assess Knowledge and Attitude toward Artificial Intelligence among Healthcare Professionals.

Annals of African medicine·2026
Same author

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jun 12, 2026

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
08:26

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

Transdermal delivery of macromolecules using solid-state biodegradable microstructures.

Janet R Wendorf1, Esi B Ghartey-Tagoe, Stephen C Williams

  • 1Corium International, Inc., 235 Constitution Drive, Menlo Park, California 94025, USA.

Pharmaceutical Research
|June 11, 2010
PubMed
Summary

MicroCor™ technology, using solid-state, biodegradable microstructures (SSBMS), effectively delivers macromolecules transdermally. This novel approach shows comparable or superior antibody responses to traditional methods.

More Related Videos

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
11:28

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

Published on: October 4, 2017

Related Experiment Videos

Last Updated: Jun 12, 2026

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
08:26

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
11:28

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

Published on: October 4, 2017

Area of Science:

  • Biotechnology
  • Materials Science
  • Drug Delivery

Background:

  • Transdermal drug delivery offers a non-invasive alternative to parenteral routes.
  • Delivery of macromolecules like proteins via the skin presents significant challenges due to the stratum corneum barrier.
  • Novel technologies are needed to facilitate efficient transdermal transport of large molecules.

Purpose of the Study:

  • To evaluate the feasibility of MicroCor™, a technology utilizing solid-state, biodegradable microstructures (SSBMS), for transdermal delivery of macromolecules.
  • To demonstrate the efficacy of SSBMS in delivering model proteins (FITC-BSA and rPA) across the skin barrier.

Main Methods:

  • Proteins FITC-BSA and rPA were incorporated into SSBMS arrays.
  • Arrays were applied to human cadaver skin (in vitro) and rat skin (in vivo).
  • Microstructure dissolution, in vitro delivery, and in vivo immune response (IgG titers) were assessed.

Main Results:

  • SSBMS arrays successfully penetrated the skin, with significant microstructure dissolution observed.
  • In vitro FITC-BSA delivery correlated with formulation protein content.
  • In vivo transdermal delivery of rPA elicited antibody titers comparable or superior to intramuscular and intradermal administration.

Conclusions:

  • MicroCor™ technology provides a convenient and effective method for transdermal macromolecule delivery.
  • SSBMS are a promising platform for non-invasive macromolecule administration.
  • This technology has the potential to enhance vaccine and therapeutic protein delivery.